Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

Allergic Rhinitis- An Updated Review for Healthcare Professionals

Aisha Abdulaziz Sadruddien[1], Abdulkarim Awadh Mashan Alotaibi[2], Saif Saud M. Alsulami[3], Abdul Aziz Ahmed Zuhayyan Al-Mazini[4], Sultan Salman Ibrahim Alobaid[5], Turki Muhayya Alotaibi[6], Khaled Abdulrahman Khaled Alrowais[7], Ahmed Traheeb B Alotaibi[8], Salman Mahmas F Alotaibi[9], Ziad Nasser Ali Al-Qahtani[10], Homud Ali Faqih[11], Faisal Tarehib Alotebe[12], Waleed Moed Samar Almutairi[13], Muqrin Mujib Awwadh Alotaibi[14]

Abstract

Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated condition characterized by nasal symptoms such as congestion, sneezing, rhinorrhea, and itching. It is prevalent globally, affecting about 15% of the population, and can significantly impact quality of life, productivity, and healthcare costs. Historically considered a localized disorder, AR is now recognized as part of a broader systemic allergic framework. The condition is categorized into seasonal, perennial, or mixed forms. Effective management relies on identifying triggers and applying appropriate pharmacologic and non-pharmacologic interventions.This review aims to provide an updated understanding of the etiology, epidemiology, diagnostic approach, and treatment strategies for AR, with a focus on practical management for healthcare professionals.A comprehensive review of current literature on allergic rhinitis, including pathophysiology, risk factors, diagnostic approaches, and treatment options. The article discusses pharmacologic therapies (e.g., corticosteroids, antihistamines), immunotherapy, and lifestyle modifications.AR pathogenesis involves both early-phase IgE-mediated responses and late-phase inflammatory processes. Environmental, genetic, and lifestyle factors influence AR prevalence. The condition affects different age groups, with seasonal forms more common in children and perennial in adults. A combination of avoidance measures, pharmacotherapy (intranasal corticosteroids, antihistamines), and allergen immunotherapy remains central to management. Emerging treatments like monoclonal antibodies (omalizumab) have shown promise for severe cases. Personalized management strategies are crucial, given the variability in treatment responses.Allergic rhinitis is a common condition with substantial personal and societal impact. Effective management involves a comprehensive approach that includes identifying and avoiding triggers, using appropriate medications, and considering advanced therapies for severe cases. With individualized treatment plans, healthcare professionals can optimize patient outcomes and reduce the burden of AR.

Keywords: *Allergic Rhinitis, Pathophysiology, Treatment, Immunotherapy, Intranasal Corticosteroids, Antihistamines, Risk Factors.*

Introduction

Allergic rhinitis (AR) is an IgE-mediated atopic disorder marked by clinical manifestations such as nasal obstruction, watery nasal discharge, sneezing, postnasal drainage, and nasal itching. It impacts approximately one in six individuals globally, contributing to substantial morbidity, reduced productivity,

[1] Ksa, Ministry of Health, Allith General Hospital
[2] Ksa, Ministry of Health, Nafi General Hospital.
[3] Ksa, Ministry of Health, Naif General Hospital.
[4] Ksa, Ministry of Health,Nefe General Hospital.
[5] Ksa, Ministry of Health, Ad Diriyah Hospital
[6] Ksa, Ministry of Health, Afif General Hospital
[7] Ksa, Ministry of Health, Dawadmi General Hospital
[8] Ksa, Ministry of Health, Nafi General Hospital
[9] Ksa, Ministry of Health, Radiology Rafaya Al-Jamsh
[10] Ksa, Ministry of Health, Primary Health Care Center in Mohammedia 2
[11] Ksa, Ministry of Health, Baish General Hospital
[12] Ksa, Ministry of Health, Shebermh Phc Rifaei Aljamsh
[13] Ksa, Ministry of Health, The Third Health Cluster in The Riyadh Region
[14] Ksa, Ministry of Health, Nafi General Hospital

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

and elevated healthcare expenditures. Traditionally, AR was perceived as a localized condition confined to the nasal passages. However, the emergence of the unified airway hypothesis has redefined AR as part of a broader systemic allergic framework, linking it to other atopic disorders, including asthma and atopic dermatitis, which share a common systemic inflammatory mechanism.[1] AR is categorized into seasonal (intermittent) or perennial (persistent) forms, with epidemiological data indicating that roughly 20% of cases are seasonal, 40% perennial, and 40% exhibit mixed characteristics.[2] Beyond nasal symptoms, individuals with AR often experience concurrent allergic conjunctivitis, non-productive cough, Eustachian tube dysfunction, and chronic sinusitis. Following diagnosis, AR management encompasses a range of therapeutic approaches, with intranasal corticosteroids representing the cornerstone of first-line treatment.[1]

Etiology

The pathogenesis of allergic rhinitis (AR) involves early and late-phase allergic responses. In the early phase, AR is driven by an immunoglobulin (Ig)E-mediated reaction to inhaled allergens, which triggers inflammation predominantly orchestrated by type 2 helper (Th2) cells.[2] This initial response occurs within five to 15 minutes of allergen exposure, leading to the degranulation of mast cells. This process releases pre-formed and newly synthesized mediators, including histamine, a key contributor to AR symptoms. Histamine induces sneezing by stimulating the trigeminal nerve and promotes rhinorrhea by activating mucous glands. Additionally, other immune mediators, such as leukotrienes and prostaglandins, contribute to nasal congestion by acting on blood vessels. Four to six hours post-exposure, the late-phase response begins, characterized by the release of cytokines like interleukins (IL)-4 and IL-13 from mast cells. These cytokines recruit eosinophils, T-lymphocytes, and basophils into the nasal mucosa, resulting in nasal edema and persistent congestion.[3] Non-IgE-mediated mechanisms also play a role in AR, particularly through eosinophilic infiltration and structural changes in the nasal mucosa. This leads to nasal hyperresponsiveness, where the mucosa becomes overly reactive to non-specific stimuli, such as tobacco smoke or cold air, triggering symptoms like sneezing, rhinorrhea, and nasal itching.[4] Genetic predisposition is another significant factor in AR etiology, although high-quality studies remain limited. Evidence from twin studies indicates a 45% to 60% concordance rate in monozygotic twins, compared to approximately 25% in dizygotic twins, highlighting a hereditary component. Furthermore, specific genetic loci on chromosomes 3 and 4 have been associated with heightened allergic responses, suggesting a genetic basis for AR susceptibility.[5]

Epidemiology

Allergic rhinitis (AR) is a widespread condition with significant global prevalence. Based on physician diagnoses, AR affects approximately 15% of the population; however, when considering self-reported nasal symptoms, this prevalence rises to an estimated 30%. The condition typically peaks during the second to fourth decades of life, after which its incidence gradually declines.[6] In the pediatric population, AR is one of the most common chronic disorders, with substantial implications for childhood health and development. Data from the International Study for Asthma and Allergies in Childhood (ISAAC) reveal that 14.6% of children aged 13 to 14 years and 8.5% of those aged 6 to 7 years exhibit symptoms of rhinoconjunctivitis associated with AR.[7] Seasonal allergic rhinitis appears to be more prevalent among children, while chronic or perennial rhinitis is more commonly observed in adults.[8]

The burden of AR extends beyond individual health, significantly impacting societal and economic domains. A 2018 systematic review highlighted that 3.6% of adults missed work due to AR, while 36% experienced reduced work performance. Economic analyses indicate that indirect costs, particularly those related to lost productivity, constitute the majority of the financial burden associated with AR.[9] These findings underscore the importance of effective management and prevention strategies to mitigate the socioeconomic impact of this condition. Several risk factors have been identified for the development of AR. These include a family history of atopy, male sex, the presence of allergen-specific IgE, a serum IgE level exceeding 100 IU/mL before the age of 6, and higher socioeconomic status.[5] Early-life exposures also play a critical role in shaping AR risk. For instance, studies have shown that children introduced to foods or formula at an early age, as well as those exposed to heavy cigarette smoke during their first year

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

of life, are at a higher risk of developing AR.[2] While recent research has explored the potential link between environmental pollution and AR, no significant correlation has been established to date.

Interestingly, certain factors may confer protection against the development of AR. The role of breastfeeding remains a topic of debate, with no conclusive evidence demonstrating its protective effect against AR. Nonetheless, breastfeeding is widely recommended due to its numerous other health benefits and absence of associated harms. Similarly, pet avoidance in childhood has not been shown to prevent AR; in fact, early exposure to pets may promote immune tolerance and reduce the risk of allergic sensitization. Another intriguing phenomenon is the "farm effect," which suggests that early-life exposure to farm environments may protect against the development of allergies. A meta-analysis of eight studies found that individuals who lived on a farm during their first year of life had a 40% lower risk of developing AR and other allergic conditions.[10] In summary, AR is a highly prevalent condition with a substantial impact on both individual health and societal resources. Its epidemiology varies across age groups, with distinct patterns observed in children and adults. While several risk factors contribute to its development, emerging evidence highlights the potential protective effects of early-life exposures, such as farm living and pet ownership. Further research is needed to elucidate these relationships and inform preventive strategies to reduce the global burden of AR.

History and Physical

A comprehensive and detailed history is a critical component in the evaluation of allergic rhinitis (AR). Clinicians should focus on identifying the types of symptoms, their timing, duration, frequency, potential triggers, exacerbating or alleviating factors, and any seasonal patterns.[10] Patients with intermittent or seasonal AR typically present with symptoms such as sneezing, rhinorrhea, and watery eyes. In contrast, those with chronic AR often report persistent complaints like postnasal drip, chronic nasal congestion, and nasal obstruction.[8] A family history of AR or a personal history of asthma is commonly observed in these patients. Individuals with intermittent AR may identify specific triggers, including exposure to pollens, animal dander, mold, humidity, perfumes, tobacco smoke, or certain materials like flooring and upholstery.[11]

During the physical examination, several characteristic findings may be observed. Patients may exhibit mouth breathing, frequent sniffling, or throat clearing. A transverse nasal crease above the tip of the nose, often seen in children due to repeated rubbing of the nose (the "allergic salute"), and dark circles under the eyes, known as allergic shiners, are also common. Anterior rhinoscopy typically reveals swollen nasal mucosa with thin, clear secretions. The inferior turbinates may appear bluish, and cobblestoning of the nasal mucosa, indicative of chronic inflammation, may be present. Whenever feasible, an internal endoscopic examination of the nasal cavity should be performed to assess nasal polyps or structural abnormalities that could contribute to symptoms. Pneumatic otoscopy is useful for evaluating eustachian tube dysfunction, a frequent finding in AR patients due to the interconnected nature of the upper airways. Palpation of the sinuses may elicit tenderness, particularly in patients with chronic symptoms, suggesting possible sinus involvement. Additionally, clinicians should carefully examine patients for signs of comorbid conditions such as asthma or atopic dermatitis, as these often coexist with AR. Patients should also be questioned about aspirin sensitivity, as this can be associated with more severe or complex cases of AR, particularly in those with nasal polyps and asthma.[11] In summary, a thorough history and physical examination are essential for accurately diagnosing AR and identifying associated conditions or complications. Attention to specific symptoms, triggers, and physical findings can guide appropriate management and improve patient outcomes.

Evaluation

Allergic rhinitis is largely a clinical diagnosis made based on a thorough history and physical. A positive response to empiric treatment with a nasal glucocorticoid can support the diagnosis. A formal diagnosis is possible with either serum testing for allergen-specific IgE or allergy skin testing [6]. As stated by the American Academy of Otolaryngology guidelines, allergy testing should be reserved for patients who are unresponsive to empiric treatment or require the identification of a specific allergen to target therapy [1].

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

Serum testing does not require trained technicians, and the patient does not need to stop taking antihistamines in advance. Intradermal allergy testing requires a trained professional, but results are available immediately. In patients with seasonal symptoms, testing should be performed during the peak symptoms season to best identify specific triggers [6]. Skin testing is known to have slightly superior sensitivity to serum testing and is more cost-effective. Contraindications to skin allergy testing include patients with uncontrolled or severe asthma, unstable cardiovascular disease, pregnancy, and/or concurrent beta-blocker therapy. H2-receptor antagonists, tricyclic antidepressants, and anti-IgE monoclonal antibody omalizumab can interfere with allergy skin test response; therefore, cessation is advisable before testing [10]. Radiographic imaging is not routinely recommended for the diagnosis of AR and is primarily used to rule out other conditions, such as rhinosinusitis [10].

Treatment / Management

The management of allergic rhinitis (AR) begins with avoidance strategies, particularly for those with seasonal symptoms. Although avoiding allergens may not always be practical, it is encouraged as a primary method of symptom control. Avoidance of dust mites, animal dander, and specific types of upholstery can help mitigate exposure, though such measures often require substantial lifestyle changes that may not be acceptable to all patients. In cases where removing a pet is not feasible, isolating the pet to a specific room can reduce dander exposure. However, even with the pet removed from the environment, it can take up to 20 weeks to fully eliminate cat dander from the home. Additional strategies such as allergen-impermeable bedding covers, washing sheets in hot water, and using vacuum cleaners equipped with high-efficiency particulate air (HEPA) filters can further reduce allergens and alleviate symptoms [5].

Pharmacological treatment options are varied and depend on the severity of symptoms. Common therapeutic agents include antihistamines, intranasal steroids, leukotriene receptor antagonists (LTRAs), and immunotherapy. Intranasal corticosteroids are considered first-line treatment for AR, either as monotherapy or in combination with oral antihistamines for patients with mild, moderate, or severe symptoms. Numerous studies have demonstrated that intranasal corticosteroids are superior to antihistamines in reducing nasal inflammation and improving mucosal pathology. These corticosteroids help manage symptoms by targeting inflammation directly in the nasal passages, with agents such as beclomethasone, budesonide, fluticasone propionate, mometasone furoate, and triamcinolone acetonide being commonly used in the United States. Correct administration of these sprays is vital for optimal efficacy and to minimize side effects. Patients should be instructed on proper technique to avoid complications. The tip of the spray should be directed laterally towards the eye to prevent direct contact with the nasal septum. Common side effects include nasal irritation and epistaxis, both of which can be minimized by proper technique [11]. Systemic steroids, both oral and injectable, have been shown to alleviate symptoms of AR; however, their use is not recommended for routine treatment due to their significant systemic side effects [10].

Antihistamines are another critical class of drugs used in the treatment of AR. First-generation antihistamines, such as diphenhydramine, chlorpheniramine, and hydroxyzine, are effective but carry notable side effects, including sedation due to their ability to cross the blood-brain barrier. These agents can also cause dry mouth, urinary retention, constipation, and tachycardia due to their action on muscarinic receptors. In contrast, second-generation antihistamines, including fexofenadine, loratadine, desloratadine, and cetirizine, are more selective for H1 receptors, less sedating, and have longer half-lives ranging from 12 to 24 hours. Among second-generation antihistamines, fexofenadine is the least sedating, while cetirizine has the most potential for sedation. Despite these differences, there is no clear evidence that one second-generation antihistamine is superior to others in terms of efficacy and safety [5]. Intranasal antihistamines, such as azelastine, are another option for AR. These medications provide a rapid onset of action and are often more effective than oral antihistamines in relieving nasal symptoms. Intranasal antihistamines can be used as first- or second-line treatments and can be combined with intranasal corticosteroids for a synergistic effect, enhancing symptom control. This combination approach can be particularly effective in managing the more severe symptoms of AR [10]. Overall, a combination of avoidance measures and pharmacological therapies, tailored to the individual's symptoms and triggers, forms the cornerstone of AR management.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

Although treatment may be symptom-based, it is essential to monitor and adjust therapy as needed to achieve optimal patient outcomes.

Leukotriene receptor antagonists (LTRAs), such as montelukast and zafirlukast, can be beneficial in the treatment of allergic rhinitis (AR). However, their efficacy is generally less than that of intranasal corticosteroids [13]. LTRAs are often utilized in combination therapy for patients with severe or refractory symptoms who do not respond adequately to other treatment options. While they may offer symptom relief, they are not considered first-line agents for the management of AR. In patients who do not achieve adequate symptom control through avoidance measures and pharmacotherapy, allergen immunotherapy is a treatment option. Immunotherapy can be delivered in the form of subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT), both of which are effective in inducing long-term remission of AR symptoms. Typically, these therapies involve weekly incremental doses for 6 to 8 months, followed by maintenance doses over 3 to 5 years. Immunotherapy often provides a prolonged, protective effect, and in many cases, therapy can be discontinued after achieving sufficient symptom control [1].

Oral decongestants, such as pseudoephedrine, are useful for temporarily relieving nasal congestion associated with AR. However, their use is limited due to their side-effect profile, including increased blood pressure, insomnia, and nervousness. Because of these potential side effects, oral decongestants are not recommended for extended daily use. Intranasal decongestants, such as xylometazoline, are alpha-agonists that produce vasoconstriction in the nasal tissue, leading to reduced congestion. However, prolonged use of intranasal decongestants can result in rebound congestion, known as rhinitis medicamentosa, making it critical to limit their use to no more than a week [10]. Sodium cromoglycate (Cromolyn) is another pharmacological option that effectively reduces symptoms such as sneezing, rhinorrhea, and nasal pruritus. It is a reasonable option for patients with mild to moderate symptoms and can be used as an adjunct to other therapies. For patients with more severe symptoms or nasal polyposis, surgical intervention may be required. Surgery is typically reserved for cases where there is intractable nasal obstruction due to inferior turbinate hypertrophy, nasal polyps, or chronic sinus disease that does not respond to medical treatments [5].

For pregnant patients experiencing symptoms of AR, budesonide is the only FDA-approved intranasal corticosteroid considered safe for use during pregnancy [1]. Monoclonal antibody therapy with omalizumab has shown efficacy in patients with AR, especially those with concomitant asthma. Omalizumab works by binding to IgE antibodies, reducing their ability to trigger allergic reactions. However, the high cost associated with omalizumab limits its widespread use, making it a more appropriate option for patients with severe, persistent symptoms that are unresponsive to other treatments [14]. Nasal saline is another adjunctive treatment, often used in combination with other therapies. Isotonic saline solutions are more beneficial in adults for nasal irrigation, while hypertonic saline solutions have been shown to be more effective in pediatric patients. Nasal saline helps to clear mucus and allergens from the nasal passages, providing symptom relief without significant side effects [10]. In conclusion, the management of AR requires a comprehensive approach that includes avoidance strategies, pharmacological treatment, and in some cases, immunotherapy or surgery. Given the variability in patient responses to different treatments, personalized management plans are essential to achieve optimal outcomes.

Differential Diagnosis

The differential diagnosis for allergic rhinitis (AR) includes several other conditions that can cause similar symptoms. Distinguishing between these conditions is important for appropriate management.

- *Vasomotor Rhinitis*: This form of noninflammatory rhinitis is triggered by environmental factors such as changes in temperature, humidity, or exposure to odors. Unlike AR, vasomotor rhinitis does not involve an allergic response but can cause similar symptoms, such as nasal congestion and rhinorrhea [10].

- *Infectious Rhinitis:* Viral or bacterial infections, most commonly seen in children, can present symptoms similar to AR. However, infectious rhinitis typically resolves with the resolution of the

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

underlying infection and may be associated with other signs of systemic illness, such as fever or malaise [6].

- *Cerebrospinal Fluid (CSF) Leak*: A CSF leak may present as clear, watery nasal discharge that is refractory to treatment. If suspected, this diagnosis warrants further investigation, such as imaging studies, to rule out any cranial or spinal abnormalities [10].

- *Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES):* In NARES, eosinophils infiltrate the nasal mucosa without an allergic trigger. Patients with NARES may experience symptoms similar to AR, but skin prick tests and serum IgE levels will be negative for allergens, helping to differentiate it from AR [2].

- *Chemical Rhinitis:* Exposure to chemicals in the workplace, household chemicals, or even certain leisure activities can cause rhinitis-like symptoms. Symptoms of chemical rhinitis often resolve after the offending chemical is removed from the environment, unlike AR, which persists despite such changes [10].

- *Rhinitis of Pregnancy and Hormonal Rhinitis*: Pregnancy-related hormonal changes can lead to rhinitis, particularly in the second and third trimesters. The symptoms are similar to AR, but the condition typically resolves after delivery, making it important to consider the patient's reproductive status [6].

- *Drug-Induced Rhinitis:* Certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), ACE inhibitors, nasal decongestants, and even cocaine, can induce rhinitis symptoms. These drugs can cause nasal congestion, rhinorrhea, and sneezing, and discontinuing the offending medication may resolve the symptoms [10].

- *Autoimmune, Granulomatous, and Vasculitic Rhinitis*: Conditions such as granulomatosis with polyangiitis, sarcoidosis, and other autoimmune or granulomatous diseases can present with rhinitis-like symptoms. These conditions are often associated with systemic signs such as skin lesions, joint involvement, or organ-specific symptoms that may help differentiate them from AR [6].

- *Nasal Polyposis:* Nasal polyps can cause chronic nasal obstruction and rhinorrhea, which can mimic the symptoms of AR. However, polyps are usually associated with more persistent, severe symptoms and may require imaging or endoscopy for diagnosis [2].

- *Nasopharyngeal Neoplasm:* Though less common, nasopharyngeal tumors can present with nasal obstruction, rhinorrhea, and epistaxis. A thorough evaluation, including imaging studies and biopsy, is needed to rule out this serious condition [10].

- *Sickle Cell Anemia:* In children, particularly those with a history of well-controlled asthma and nasal polyposis, sickle cell anemia should be considered. Sweat chloride testing is an appropriate next step to rule out cystic fibrosis, a condition that may also present similar symptoms, such as nasal polyps and respiratory symptoms [6].

In children under the age of 2 years, it is also important to assess for congenital causes of nasal obstruction, such as choanal atresia or underlying immunodeficiencies, which can manifest with similar nasal symptoms [2]. A thorough clinical history, physical examination, and appropriate diagnostic testing are essential for accurately diagnosing AR and distinguishing it from other conditions with similar presentations.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

Pertinent Studies and Ongoing Trials

Recent studies have provided significant insights into the management and treatment of allergic rhinitis (AR), with intranasal corticosteroids standing out as the most effective first-line therapy. In comparison to topical and oral antihistamines, intranasal corticosteroids have demonstrated superior efficacy in alleviating common AR symptoms such as sneezing, rhinorrhea, nasal pruritis, and nasal blockage. Due to these benefits, intranasal corticosteroids are now widely recommended as the first-choice treatment for AR patients [15]. In addition to corticosteroids, immunotherapy has garnered substantial support in the literature as a disease-modifying treatment for both AR and allergic asthma. Immunotherapy, which involves gradually exposing patients to increasing doses of allergens to desensitize the immune system, is considered the only intervention known to alter the course of allergic diseases. Studies consistently highlight its effectiveness in reducing symptoms and enhancing quality of life for patients with AR. The treatment is typically administered through either subcutaneous or sublingual routes, both of which have shown long-term benefits [16].

Despite these advances, new treatment modalities are continuously being explored. One area of active research is Anti-H3 and H4 antihistamines, which aim to block histamine receptors involved in inflammatory pathways associated with AR. However, these agents have not yet received regulatory approval, and their clinical utility remains under investigation. Preliminary data suggests they could provide a novel approach for patients who are refractory to conventional therapies. Another promising development is the use of Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor. Originally approved for chronic obstructive pulmonary disease (COPD), Roflumilast has shown potential in a small study to improve AR symptoms. Although the results are encouraging, further studies are necessary to confirm these findings and determine the optimal patient population for this therapy.

In the realm of immunotherapy, researchers are exploring novel administration routes, such as the direct injection of allergens into lymph nodes. Early studies indicate that this method induces a significantly stronger allergen-specific immune response (up to ten times higher) compared to traditional methods, which may lead to improved efficacy and a better safety profile. This approach is still in the experimental stages, but it represents an exciting direction for future treatment strategies. Additionally, Dapilumab, a fully humanized monoclonal antibody that inhibits IL-4 and IL-13 signaling pathways, has shown promise in recent clinical trials. In a randomized, double-blind, placebo-controlled study, Dapilumab significantly improved nasal symptoms associated with AR. The drug works by targeting the key cytokines involved in the inflammatory process, providing a targeted approach to managing AR symptoms. Ongoing studies will help clarify its long-term efficacy and safety in broader patient populations [16]. These emerging therapies highlight the evolving landscape of AR treatment. While traditional treatments such as intranasal corticosteroids and immunotherapy remain effective, novel approaches such as new antihistamines, PDE4 inhibitors, lymph node injections, and monoclonal antibodies are beginning to offer promising alternatives for patients with moderate to severe AR. Clinical trials will continue to refine these therapies, and their potential to enhance patient outcomes in AR treatment is significant.

Prognosis

Allergic rhinitis (AR) is often considered a chronic condition with varying degrees of severity over time. The prevalence of AR tends to peak during adolescence and generally decreases with advancing age. This trend suggests that many patients may experience symptom relief as they age, possibly due to changes in the immune system or other environmental factors. Longitudinal studies support this observation. A notable 23-year follow-up study found that 54.9% of patients reported an improvement in symptoms, with 41.6% becoming symptom-free over time. Furthermore, patients who experienced the onset of AR at a younger age were more likely to show significant improvement as they aged, indicating a potential correlation between age of onset and long-term prognosis [17]. The severity of AR can fluctuate over time and is influenced by various factors, including environmental conditions, geographic location, and seasonal allergens. For instance, patients residing in areas with high levels of airborne pollen may experience exacerbated symptoms during specific seasons, such as spring or summer, when allergens are most prevalent. This seasonal variation contributes to the intermittent nature of AR symptoms, with patients

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

experiencing periods of exacerbation followed by periods of relative symptom relief. Treatment interventions, such as allergen immunotherapy, have shown promising results in improving long-term symptom control. In a study examining the long-term effects of grass allergy immunotherapy, approximately 50% of patients experienced significant improvement in symptoms, with benefits persisting for up to three years after the therapy had been discontinued [18]. This suggests that allergen immunotherapy can provide lasting relief and may even modify the course of the disease for some patients, offering a degree of long-term symptom control. While AR remains a chronic condition for many individuals, the prognosis is generally favorable, particularly with appropriate management strategies. Patients who receive effective treatment, including allergen avoidance, pharmacotherapy, or immunotherapy, are more likely to experience improved symptoms and quality of life over time. Moreover, as research continues to uncover new therapeutic options, patients may have access to more personalized and effective treatments, further enhancing long-term outcomes.

Complications

Chronic rhinosinusitis (CRS) is a significant complication of allergic rhinitis (AR), despite being a distinct condition. CRS is characterized by prolonged nasal inflammation, with symptoms such as nasal congestion, discharge, and sinus pressure, lasting for more than three months. One of the hallmark features of chronic rhinosinusitis is the presence of nasal polyps, which form due to persistent inflammation of the paranasal sinus mucosa. Nasal polyps are typically bilateral and benign, though they can lead to significant discomfort and obstruction. In rare cases, unilateral nasal polyps can signal underlying malignancy and should be further investigated. The overall incidence of nasal polyps in the general population is approximately 4%, with males being more commonly affected. Treatment options for nasal polyps include topical steroids and saline irrigation, though surgical intervention may be necessary for patients who do not respond to medical management [1]. Sensitization to allergens in AR can also lead to immunological changes in the adenoids, potentially causing adenoid hypertrophy. This can contribute to further nasal obstruction and exacerbate symptoms of AR. Additionally, eustachian tube dysfunction (ETD) is frequently observed in patients with AR, causing symptoms such as ear fullness, otalgia (ear pain), and ear popping. Eustachian tube dysfunction may also lead to complications such as otitis media with effusion, resulting in fluid accumulation in the middle ear and increased susceptibility to infections.

A significant number of patients with AR also have concurrent asthma, with studies suggesting that 10 to 40% of AR patients experience asthma symptoms. The association is particularly strong in patients with moderate to severe persistent rhinitis. AR is considered an independent risk factor for the development of asthma, especially when AR is diagnosed in infancy. This connection highlights the need for careful monitoring and management of both conditions to improve overall respiratory health. In addition to asthma, other complications of AR can include persistent cough, which may be related to postnasal drip, and eosinophilic esophagitis, a condition in which inflammation occurs in the esophagus, potentially exacerbated by allergic responses. The relationship between AR and eosinophilic esophagitis is still being investigated, and more research is required to fully understand the connection and its clinical significance [10]. Allergen desensitization through allergy shots (immunotherapy) is another treatment option that can potentially lead to severe complications. Although immunotherapy is effective for many patients, it carries the risk of acute exacerbations of rhinitis or asthma. In rare cases, patients may progress to anaphylaxis, a life-threatening allergic reaction. Due to this risk, it is crucial that healthcare providers administering allergen desensitization be well-prepared to recognize and manage severe reactions. Clinics should be equipped with emergency medications, particularly epinephrine, and appropriate airway management tools to handle such situations effectively [19][20].

Consultations

Allergic rhinitis (AR) is primarily diagnosed and managed by primary care physicians (PCPs) or general practitioners. However, if patients do not respond to standard treatments, they may require referral to a specialist. Allergists and otolaryngologists (ENTs), especially those with expertise in allergies, are the most common specialists consulted. This referral typically happens when:

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

- Patients are candidates for immunotherapy.
- Traditional therapies fail to provide relief.
- There are physical findings that warrant specialized attention, such as multiple nasal polyps in a child, which may indicate a more serious condition like cystic fibrosis.
- Unilateral nasal discharge or bloody discharge is present, suggesting potential malignancy.
- There are concerns about a cerebrospinal fluid (CSF) leak, which could be causing rhinorrhea.

In these cases, urgent referral to an ENT specialist is recommended to rule out serious conditions and initiate further investigations [21].

Deterrence and Patient Education

Patients with AR often underestimate the severity of their condition, resulting in delayed or inadequate treatment. It's essential to adequately control AR due to its established link to asthma. Poorly controlled rhinitis often correlates with poor asthma management, making early intervention crucial. The following strategies can help improve patient outcomes:

- *Patient compliance* with prescribed treatments is critical. A lack of adherence to medication regimens can hinder symptom control and quality of life.
- *Education on Treatment*: Providing educational materials about AR is fundamental for empowering patients. These materials should include information on the symptoms, triggers, and treatment options for AR.
- *Nasal Spray Techniques*: Correct use of nasal sprays is vital for effective treatment. Patients should be instructed on proper administration—spraying the medication just inside the nostril while aiming toward the outer wall. It's important for patients not to take a deep breath or sniff hard after spraying, as this can reduce the drug's effectiveness and cause irritation [15].
- *Avoidance Of Allergens*: While allergen avoidance is crucial, it requires significant effort and can be challenging. Educating patients on the importance of minimizing exposure to known triggers such as pollen, pet dander, or dust mites is important, even though it may be a time-consuming task [23].

Enhancing Healthcare Team Outcomes

The ecology of medical care model highlights that only a small proportion of patients actively seek medical attention for their AR symptoms. Most patients are managed by their PCP or nurse practitioners. However, it is important to equip patients with information on self-management and guidance on when to contact their PCP for further evaluation or adjustments to their treatment plan. This model emphasizes the involvement of various healthcare professionals in managing AR:

- *Community Pharmacists* and nurse practitioners can play a crucial role in educating patients, offering guidance on over-the-counter treatments, and assisting with medication management.
- *Referral To Specialists*: If patients fail traditional treatments or require immunotherapy, a referral to allergists or ENT specialists is necessary for more specialized care.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

- *Co-management*: Once a treatment plan is established, PCPs, nurse practitioners, and allergy specialists should work together to monitor patient progress and adjust therapies as needed. If symptoms persist or worsen, further evaluations are necessary.

Collaboration between PCPs, pediatricians, allergists, and ENT specialists is key to optimizing patient care. Additionally, involving specialty-trained ENT nurses and other clinicians can enhance the management of AR, especially when symptoms are difficult to control or associated with complex complications [21]. The successful management of AR requires a team-based approach, where each member brings their expertise to improve patient outcomes.

Role of Healthcare Providers in Allergic Rhinitis

Healthcare providers play a crucial role in the diagnosis, management, and prevention of allergic rhinitis (AR). Given its prevalence and impact on patients' quality of life, healthcare providers must offer a comprehensive, patient-centered approach to effectively manage the condition. Their role spans multiple areas, from early detection and accurate diagnosis to personalized treatment and ongoing patient education.

Diagnosis and Assessment

The first step in managing AR is an accurate diagnosis. Healthcare providers must differentiate AR from other conditions with similar symptoms, such as viral infections or sinusitis. Diagnosis begins with a thorough patient history, including symptom onset, frequency, and severity. A physical examination, focusing on nasal passages and sinuses, is crucial to identifying signs such as nasal polyps, clear discharge, and mucosal swelling. In some cases, allergy testing, either through skin prick tests or serum IgE measurement, is necessary to confirm specific allergens that trigger symptoms. It is essential for healthcare providers to recognize that AR may coexist with other allergic conditions, such as asthma or atopic dermatitis. Thus, a comprehensive approach is necessary, addressing not only nasal symptoms but also any systemic manifestations of allergic disease.

Management and Treatment

Once diagnosed, healthcare providers are responsible for developing an individualized treatment plan for patients. Pharmacologic treatments are the cornerstone of AR management, with corticosteroids and antihistamines being the most commonly prescribed medications. Intranasal corticosteroids (INS) are considered the first-line treatment due to their efficacy in reducing inflammation and controlling symptoms. They work by decreasing the immune response to allergens and alleviating nasal congestion and rhinorrhea. Antihistamines, both systemic and intranasal, are often used to control symptoms like sneezing and itching. Healthcare providers should also educate patients on the proper use of these medications, especially corticosteroids, to ensure adherence and maximize their effectiveness. This includes demonstrating the correct technique for using nasal sprays, as improper use can reduce their efficacy. In addition to pharmacologic treatments, immunotherapy is another important option, particularly for patients with moderate to severe symptoms or those who do not respond adequately to medications. Allergen-specific immunotherapy (allergy shots) or sublingual immunotherapy (SLIT) gradually desensitizes the immune system to specific allergens, leading to long-term symptom relief. Healthcare providers must assess the patient's suitability for immunotherapy, considering their medical history, the severity of symptoms, and their willingness to undergo a long-term treatment. Non-pharmacologic interventions also form an essential part of managing AR. Healthcare providers should encourage patients to identify and avoid potential environmental triggers, such as pollen, dust mites, or pet dander. This can involve practical advice on creating allergen-free environments, such as using air purifiers, washing bedding regularly, and avoiding outdoor activities during high pollen seasons. Lifestyle modifications, such as maintaining a healthy diet and managing stress, may also play a supportive role in symptom control.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

Patient Education and Support

Equally important is the role of healthcare providers in patient education. Many patients are unaware of the potential long-term effects of uncontrolled AR, such as sleep disturbances, poor academic or work performance, and an increased risk of developing asthma. Healthcare providers must inform patients about the chronic nature of AR and the importance of consistent management. Regular follow-up appointments are necessary to assess treatment effectiveness, adjust medications, and address any side effects. Furthermore, providing emotional and psychological support is crucial, as AR can significantly impact a patient's well-being, especially when symptoms are persistent or severe. In conclusion, healthcare providers are central to the effective management of allergic rhinitis. From accurate diagnosis to tailored treatment plans and patient education, their role is multifaceted and critical in improving patient outcomes. Through a combination of pharmacologic and non-pharmacologic interventions, alongside ongoing support, healthcare providers can help patients manage the condition, reduce its impact on daily life, and prevent long-term complications.

Conclusion

Allergic rhinitis (AR) is a prevalent condition that imposes a significant burden on both individuals and healthcare systems. It is increasingly recognized as part of a broader allergic syndrome, often coexisting with other atopic diseases such as asthma and atopic dermatitis. The pathophysiology of AR involves complex immune responses, with both early-phase IgE-mediated reactions and a subsequent late-phase inflammatory response contributing to the characteristic nasal symptoms. These responses are triggered by a wide range of environmental allergens, which vary by geography, climate, and individual susceptibility. The clinical presentation of AR can range from intermittent, seasonal symptoms to persistent, chronic discomfort, affecting all age groups, though with different patterns in children and adults. In children, seasonal AR is more common, while in adults, perennial forms dominate. This variance underscores the need for precise diagnostic approaches that include a detailed patient history and physical examination, complemented by allergen-specific testing when necessary. While not routinely required, testing can help pinpoint specific allergens and tailor treatment strategies accordingly. The management of AR is multifaceted, involving both non-pharmacologic and pharmacologic interventions. Non-pharmacologic strategies include allergen avoidance measures, though they are not always feasible or effective for all patients. Pharmacologic treatments, particularly intranasal corticosteroids, are first-line therapies, with antihistamines, leukotriene receptor antagonists (LTRAs), and immunotherapy serving as adjuncts in more severe cases. Advances in biologic therapies, such as omalizumab, have expanded the treatment arsenal for patients with persistent or severe symptoms. However, the high cost and limited access to such therapies highlight the need for a cost-effective, patient-centered approach. For effective treatment, healthcare professionals must tailor therapies based on symptom severity and response to previous treatments. Combining pharmacologic treatments with lifestyle adjustments offers the best outcomes. As AR is a chronic condition, ongoing management, monitoring, and adjustment are critical in reducing symptom burden and improving patient quality of life. Further research into genetic and environmental factors, as well as new therapeutic approaches, will continue to shape the future management of allergic rhinitis.

References

Kakli HA, Riley TD. Allergic Rhinitis. Prim Care. 2016 Sep;43(3):465-75.
Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001 Jul;108(1 Suppl):S2-8.
Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy. 2011 Oct;1(3):157-67.
Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. 2010 Apr;2(2):65-76.
Tran NP, Vickery J, Blaiss MS. Management of rhinitis: allergic and non-allergic. Allergy Asthma Immunol Res. 2011 Jul;3(3):148-56.
Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015 Jan 29;372(5):456-63.
Mir E, Panjabi C, Shah A. Impact of allergic rhinitis in school going children. Asia Pac Allergy. 2012 Apr;2(2):93-100.
Varshney J, Varshney H. Allergic Rhinitis: an Overview. Indian J Otolaryngol Head Neck Surg. 2015 Jun;67(2):143-9.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

Vandenplas O, Vinnikov D, Blanc PD, Agache I, Bachert C, Bewick M, Cardell LO, Cullinan P, Demoly P, Descatha A, Fonseca J, Haahtela T, Hellings PW, Jamart J, Jantunen J, Kalayci Ö, Price D, Samolinski B, Sastre J, Tian L, Valero AL, Zhang X, Bousquet J. Impact of Rhinitis on Work Productivity: A Systematic Review. J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1274-1286.e9.

Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, Azar A, Baroody FM, Bachert C, Canonica GW, Chacko T, Cingi C, Ciprandi G, Corey J, Cox LS, Creticos PS, Custovic A, Damask C, DeConde A, DelGaudio JM, Ebert CS, Eloy JA, Flanagan CE, Fokkens WJ, Franzese C, Gosepath J, Halderman A, Hamilton RG, Hoffman HJ, Hohlfeld JM, Houser SM, Hwang PH, Incorvaia C, Jarvis D, Khalid AN, Kilpeläinen M, Kingdom TT, Krouse H, Larenas-Linnemann D, Laury AM, Lee SE, Levy JM, Luong AU, Marple BF, McCoul ED, McMains KC, Melén E, Mims JW, Moscato G, Mullol J, Nelson HS, Patadia M, Pawankar R, Pfaar O, Platt MP, Reisacher W, Rondón C, Rudmik L, Ryan M, Sastre J, Schlosser RJ, Settipane RA, Sharma HP, Sheikh A, Smith TL, Tantilipikorn P, Tversky JR, Veling MC, Wang Y, Westman M, Wickman M, Zacharek M. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018 Feb;8(2):108-352.

Small P, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2011 Nov 10;7 Suppl 1(Suppl 1):S3.

Yáñez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002 Nov;89(5):479-84.

Ratner PH, Howland WC, Arastu R, Philpot EE, Klein KC, Baidoo CA, Faris MA, Rickard KA. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol. 2003 May;90(5):536-42.

Masieri S, Cavaliere C, Begvarfaj E, Rosati D, Minni A. Effects of omalizumab therapy on allergic rhinitis: a pilot study. Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5249-5255.

Scadding GK. Optimal management of allergic rhinitis. Arch Dis Child. 2015 Jun;100(6):576-82.

Heffler E, Brussino L, Del Giacco S, Paoletti G, Minciullo PL, Varricchi G, Scadding G, Malvezzi L, De Virgilio A, Spriano G, Puggioni F, Fornero M, Rolla G, Canonica GW. New drugs in early-stage clinical trials for allergic rhinitis. Expert Opin Investig Drugs. 2019 Mar;28(3):267-273.

Greisner WA, Settipane RJ, Settipane GA. Natural history of hay fever: a 23-year follow-up of college students. Allergy Asthma Proc. 1998 Sep-Oct;19(5):271-5.

Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010 Jan;125(1):131-8.e1-7.

Rodríguez Del Río P, Vidal C, Just J, Tabar AI, Sanchez-Machin I, Eberle P, Borja J, Bubel P, Pfaar O, Demoly P, Calderón MA. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment. Pediatr Allergy Immunol. 2017 Feb;28(1):60-70.

Cingi C, Wallace D, Bayar Muluk N, Ebisawa M, Castells M, Şahin E, Altıntoprak N. Managing anaphylaxis in the office setting. Am J Rhinol Allergy. 2016 Jul;30(4):118-23.

Ryan D, van Weel C, Bousquet J, Toskala E, Ahlstedt S, Palkonen S, van den Nieuwenhof L, Zuberbier T, Wickman M, Fokkens W. Primary care: the cornerstone of diagnosis of allergic rhinitis. Allergy. 2008 Aug;63(8):981-9.

Lipworth B, Newton J, Ram B, Small I, Schwarze J. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 2017 Jan 23;27(1):3.

Rosenwasser LJ. Treatment of allergic rhinitis. Am J Med. 2002 Dec 16;113 Suppl 9A:17S-24S.

Akhouri, S., & House, S. A. (2023). Allergic rhinitis. In StatPearls [Internet]. StatPearls Publishing.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13121 – 13133
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6190

التهاب الأنف التحسسي - مراجعة محدثة للمهنيين الصحيين

الملخص:

الخلفية: التهاب الأنف التحسسي (AR) هو حالة معتمدة على الأجسام المضادةIgE ، تتميز بأعراض أنفية مثل الاحتقان، والعطس، وسيلان الأنف، والحكة. يعد شائعًا على مستوى العالم، حيث يؤثر على حوالي 15% من السكان، ويمكن أن يؤثر بشكل كبير على جودة الحياة والإنتاجية وتكاليف الرعاية الصحية. كان يُعتبر تاريخيًا اضطرابًا محليًا، لكن يتم الآن التعرف عليه كجزء من إطار تحسسي نظامي أوسع. تُصنف الحالة إلى أشكال موسمية، دائمة، أو مختلطة. يعتمد العلاج الفعال على تحديد المحفزات وتطبيق التدخلات الدوائية وغير الدوائية المناسبة.

الهدف: تهدف هذه المراجعة إلى توفير فهم محدث لعلم الأسباب والوبائيات، ونهج التشخيص، واستراتيجيات العلاج لالتهاب الأنف التحسسي، مع التركيز على الإدارة العملية للمهنيين الصحيين.

الطرق :مراجعة شاملة للأدبيات الحالية حول التهاب الأنف التحسسي، بما في ذلك الفيزيولوجيا المرضية، وعوامل الخطر، ونهج التشخيص، وخيارات العلاج. يناقش المقال العلاجات الدوائية (مثل الكورتيكوستيرويدات، مضادات الهيستامين)، والعلاج المناعي، وتعديلات نمط الحياة.

النتائج :يشمل منشأ التهاب الأنف التحسسي استجابات IgE المعتمدة في المرحلة المبكرة وعمليات الالتهاب في المرحلة المتأخرة. تؤثر العوامل البيئية، والوراثية، ونمط الحياة على انتشار التهاب الأنف التحسسي. تؤثر الحالة على فئات عمرية مختلفة، حيث تكون الأشكال الموسمية أكثر شيوعًا في الأطفال والأشكال الدائمة في البالغين. لا يزال الجمع بين تدابير تجنب المحفزات، والعلاج الدوائي (الكورتيكوستيرويدات الأنفية، مضادات الهيستامين)، والعلاج المناعي للحساسية هو الأساس في العلاج. أظهرت العلاجات الجديدة مثل الأجسام المضادة وحيدة النسيلة (أومالیزوماب) نتائج واعدة للحالات الشديدة. تُعتبر استراتيجيات العلاج الشخصية أمرًا بالغ الأهمية، نظرًا لتفاوت استجابة المرضى للعلاج.

الخاتمة :التهاب الأنف التحسسي هو حالة شائعة ذات تأثير كبير على المستوى الشخصي والمجتمعي. يشمل العلاج الفعال نهجًا شاملاً يتضمن تحديد وتجنب المحفزات، واستخدام الأدوية المناسبة، والنظر في العلاجات المتقدمة للحالات الشديدة. من خلال خطط علاج مخصصة، يمكن للمهنيين الصحيين تحسين نتائج المرضى وتقليل عبء التهاب الأنف التحسسي.

الكلمات المفتاحية: التهاب الأنف التحسسي، الفيزيولوجيا المرضية، العلاج، العلاج المناعي، الكورتيكوستيرويدات الأنفية، مضادات الهيستامين، عوامل الخطر.